Status: Recruiting
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects
This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM0504 following daily oral administrations in non-diabetic overweight or obese adult subjects.
Participants needed: 80
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: BrightGene Bio-Medical Technology Co., Ltd.Updated: Sep 19, 2025Locations: 1
Eligibility criteria
Between ≥ 30.0 kg/m2 and ≤ 40.0 kg/m2 (obese); OR [+3]
Have allergic predisposition (allergic to 3 or more foods or drugs), or are alle... [+5]